Search
Jul 16
Daiichi Sankyo's global head of R&D talks antibody-drug conjugates and more at the company's "Pharma Day" event in Kendall Square
From a partnering event being held at MassBio's HQ in Kendall Square, Ken Takeshita describes Daiichi's targets under development beyond...
Jun 2
Daiichi Sankyo's leadership comments on DESTINY-Breast06 at #ASCO24
Global Head of Oncology Ken Keller and Chief Operating Officer Hiroyuki Okuzawa describe the significance of today's data and also...
Jan 10
A deep dive into antibody-drug conjugates with Daiichi Sankyo's Ken Keller
Ken Keller describes recent advances in ADC technology, talks about the recent Merck deal, and what it was like to change breast cancer.
.png){kind=logo}
